Zura Bio Limited (ZURA) Key Metrics
ZURA valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $371.8M
- Enterprise value
- $208.8M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 2.1 10-yr median 2.6
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.01
ZURA key metrics, 2021–2025
Fiscal year ended December 31, 2025 · U.S. dollarsZURA valuation Price multiples at each fiscal year-end price.
ZURA returns How much profit the business earns on the capital it uses.
ZURA per-share figures Results divided by the shares outstanding at year-end.
ZURA financial health Debt, liquidity and how easily interest is covered.
ZURA efficiency & capital use Working capital cycle and where the cash goes.
ZURA valuation history
ZURA returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ZURA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ZURA price vs earnings per share
ZURA key metrics
2021–2025| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Valuation | |||||
| Market capitalization | $493.4M | $187.7M | $154.4M | — | — |
| Enterprise value | $384.0M | $11.2M | $54.6M | — | — |
| Price / book | 4.9 | 1.3 | 2.6 | — | — |
| Earnings yield | −13.9% | −27.9% | −39.1% | — | — |
| Free cash flow yield | −13.2% | −15.0% | −14.9% | — | — |
| Share price at fiscal year-end | $5.24 | $2.50 | $4.67 | — | — |
| Per share | |||||
| Revenue per share | $0.00 | $0.00 | $0.00 | — | — |
| Earnings per share | −$0.73 | −$0.70 | −$1.83 | — | — |
| Operating cash flow per share | −$0.69 | −$0.37 | −$0.46 | — | — |
| Free cash flow per share | −$0.69 | −$0.37 | −$0.70 | — | — |
| Cash per share | $1.16 | $2.35 | $3.02 | — | — |
| Book value per share | $1.08 | $1.96 | $1.79 | — | — |
| Tangible book value per share | $1.08 | $1.96 | $1.79 | — | — |
| Capex per share | $0.00 | $0.00 | $0.24 | — | — |
| Shares outstanding | 94.2M | 75.1M | 33.1M | — | — |
| Change in shares outstanding | +25.4% | +127.0% | — | — | — |
| Returns & profitability | |||||
| Return on equity (ROE) | −55.3% | −50.8% | −442.6% | — | 6.5% |
| Return on invested capital (ROIC) | — | — | — | — | −0.8% |
| Return on assets (ROA) | −46.8% | −37.4% | −113.8% | −35.3% | 6.0% |
| Return on tangible assets | −60.2% | −29.2% | −59.9% | −489.1% | 6.0% |
| Income quality (OCF / net income) | — | — | — | — | −0.13 |
| Financial health | |||||
| Total debt | — | — | — | $7.8M | — |
| Cash & short-term investments | $109.4M | $176.5M | $99.8M | $1.6M | $729,223 |
| Net debt | −$109.4M | −$176.5M | −$99.8M | $6.2M | −$729,223 |
| Debt / assets | — | — | — | 1.47 | — |
| Net debt / EBITDA | — | — | — | — | −0.09 |
| Current ratio | 9.05 | 9.16 | 4.97 | 0.12 | 4.23 |
| Quick ratio | 9.05 | 9.16 | 4.97 | 0.12 | 4.23 |
| Working capital | $99.9M | $159.2M | $80.5M | −$13.0M | $879,825 |
| Invested capital | −$7.9M | −$29.7M | −$40.5M | −$25.9M | $129.5M |
| Tangible asset value | $101.5M | $160.0M | $79.6M | −$22.1M | $130.2M |
| Net current asset value | $99.9M | $159.2M | $79.6M | −$25.5M | −$9.2M |
| Graham net-net per share | $1.03 | $2.09 | $2.37 | — | — |
| Capital allocation | |||||
| Capex / depreciation | 2.31 | 8.33 | 47.65 | 52.52 | 0.00 |
| Efficiency | |||||
| Days payables outstanding | 7,493.7 | 70,607.2 | — | — | — |
| Payables turnover | 0.05 | 0.01 | — | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average payables | $1.0M | $1.7M | $2.4M | $1.0M | $7,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from ZURA's annual financial statements (latest annual report filed March 19, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ZURA valuation and financial ratios
Zura Bio earned a return on equity of −55.3% in fiscal 2025.
See the ZURA income statement, the ZURA chart for price history, or the ZURA stock overview for the latest quote and news.
ZURA key metrics FAQ
What is Zura Bio's return on equity?
Zura Bio's return on equity (ROE) was −55.3% in fiscal 2025: net income of -$68.7 million on average shareholders' equity of $124.2 million.
What is Zura Bio's free cash flow yield?
Zura Bio generated -$64.9 million of free cash flow in fiscal 2025, a free cash flow yield of −13.2% on its market value at year-end ($493.4 million).
What is Zura Bio's current ratio?
Zura Bio's current ratio was 9.05 at the end of fiscal 2025: current assets were 9.05 times current liabilities.